{"title": "Coronavirus disease-19: The First 7,755 Cases in the Republic of Korea", "doi": "10.1101/2020.03.15.20036368", "citation_id": "2020.03.15.20036368v1", "date": "2020-03-18", "laguage": "en", "journal_title": "medRxiv", "first_page": "2020.03.15.20036368", "abstract": "<p>We report the first 7,755 patients with confirmed COVID19 in Korea as of March 13, 2020. A total of 66 deaths were identified, resulting case fatality proportion of 0.9%. Older people, and those with coexisting medical conditions were at risk for fatal outcomes. The highest number of cases were from Daegu, followed by Gyeongbuk, with elevated age-stratified case fatality. This summary may help to understand the disease dynamics in the early phase of COVID19 outbreak, therefore, to guide future public health measures.</p>", "twitter_description": "We report the first 7,755 patients with confirmed COVID19 in Korea as of March 13, 2020. A total of 66 deaths were identified, resulting case fatality proportion of 0.9%. Older people, and those with coexisting medical conditions were at risk for fatal outcomes. The highest number of cases were from Daegu, followed by Gyeongbuk, with elevated age-stratified case fatality. This summary may help to understand the disease dynamics in the early phase of COVID19 outbreak, therefore, to guide future public health measures.\n\n### Competing Interest Statement\n\nThe authors have declared no competing interest.\n\n### Funding Statement\n\nNone exist\n\n### Author Declarations\n\nAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.\n\nYes\n\nAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.\n\nYes\n\nI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).\n\nYes\n\nI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.\n\nYes\n\nKorea CDC", "full_text_html_url": "https://www.medrxiv.org/content/10.1101/2020.03.15.20036368v1.full", "public_url": "https://www.medrxiv.org/content/10.1101/2020.03.15.20036368v1", "abstract_html_url": "https://www.medrxiv.org/content/10.1101/2020.03.15.20036368v1.abstract", "pdf_url": "https://www.medrxiv.org/content/medrxiv/early/2020/03/18/2020.03.15.20036368.full.pdf", "rights": "\u00a9 2020, Posted by Cold Spring Harbor Laboratory. The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission.", "publisher": "Cold Spring Harbor Laboratory Press", "pisa": "medrxiv;2020.03.15.20036368v1", "access_rights": "restricted", "authors": ["COVID-19 National Emergency Response Center Korea Centers for Disease Control and Prevention", "Young June Choe"]}